Development of BMS 986094 (BMS/Inhibitex) for Hepatitis C halted - 26-Aug-2012

BMS/Inhibitex have discontinued development of BMS 986094, for Hepatitis C, following the death of a participant in a Phase II trial. A spokesperson stated that the decision "was made in the interest of patient safety, based on a rapid, thorough and ongoing assessment of patients". The trial was voluntarily suspended on 1 August 2012. The company states that while "the cause of these unexpected events, which involve heart and kidney toxicity, has not been definitively established…it is in the best interest of patients to halt development of BMS 986094".

Related News

Related Hepatology Information

Back to top

Latest News

10 May 2015
20 May 2013
20 May 2013